Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1921-1927

  Ananthakrishnan, Ashwin N ^a,b   Cagan, Andrew ^c   Gainer, Vivian S ^c   Cai, Tianxi ^d   Cheng, Su Chun ^d   Savova, Guergana ^e   Chen, Pei ^e   Szolovits, Peter ^f   Xia, Zongqi ^a,b   De Jager, Philip L ^a,b   Shaw, Stanley Y ^a,b   Churchill, Susanne ^g   Karlson, Elizabeth W ^c,g   Kohane, Isaac ^b,e,g   Plenge, Robert M ^c,g   Murphy, Shawn N ^a,b,c,e   Liao, Katherine P ^b,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS HEALTHCARE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Crohn's disease; Hospitalization; Surgery; Ulcerative colitis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; COLITIS; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SURGICAL RISK; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TERTIARY CARE CENTERS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84884644789     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182902ad9     Document Type: Article

References (35)

1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140: 1785-1794.
2. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut. 2012;61:622-629.
3. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011;17: 2558-2565.
4. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
5. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235.
6. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
7. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
8. Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl. 2005;76:11-20.
9. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136-1142.
10. Cantorna MT, Zhu Y, Froicu M, et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80: 1717S-1720S.
11. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2:308-315.
12. Narula N, Marshall JK. Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis. 2012;6:397-404.
13. Nicholson I, Dalzell AM, El-Matary W. Vitamin D as a therapy for colitis: a systematic review. J Crohns Colitis. 2012;6:405-411.
14. Garg M, Lubel JS, Sparrow MP, et al. Review article: vitamin D and inflammatory bowel disease-established concepts and future directions. Aliment Pharmacol Ther. 2012;36:324-344.
15. Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012; 61:1686-1692.
16. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012;142:482-489.
17. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35: 308-316.
18. Joseph AJ, George B, Pulimood AB, et al. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130:133-137.
19. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004;39: 527-533.
20. Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648-2652.
21. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
22. Ananthakrishnan AN, Cai T, Savova G, et al. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis. 2013;19:1411-1420.
23. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713-716.
24. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
25. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011; 364:248-254.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
27. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889-896.
28. Daniel C, Radeke HH, Sartory NA, et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther. 2006; 319:622-631.
29. Zhu Y, Mahon BD, Froicu M, et al. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217-224.
30. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15: 1656-1662.
31. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352-1360.
32. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol. 2011;106:699-712.
33. Wu S, Xia Y, Liu X, et al. Vitamin D receptor deletion leads to reduced level of IkappaBalpha protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol. 2010;42:329-336.
34. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285: 2227-2231.
35. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.